When is the next results date for Amanta Healthcare Ltd?

The next results date for Amanta Healthcare Ltd is scheduled for 19 May 2026.

Should I buy, sell or hold Amanta Healthcare Ltd?

Based on the current analysis of Amanta Healthcare Ltd, it appears that selling might be the most prudent option at this time. The company has shown weak long-term fundamental strength, with a negative compound annual growth rate (CAGR) of -2.00% in net sales over the last five years. Additionally, the high Debt to EBITDA ratio of 4.08 times indicates a low ability to service its debt, which raises concerns about financial stability.The operating profit to net sales ratio is currently at its lowest at 19.42%, reflecting flat results as of March 2026. While the company has an attractive valuation with a return on capital employed (ROCE) of 11.1 and a favorable enterprise value to capital employed ratio of 1.7, these factors may not be enough to offset the underlying weaknesses.On a more positive note, institutional investors have increased their stake by 1.38% in the last quarter, now holding 13.72% of the company. This could indicate some level of confidence in the company's potential, as institutional investors typically have more resources to analyze the fundamentals.However, given the concerning financial metrics and the overall weak growth outlook, it may be wise to consider selling your shares in Amanta Healthcare Ltd.

Which are the latest news on Amanta Healthcar?

Amanta Healthcare Ltd is Rated Sell Amanta Healthcare’s Volatile Week: 0.58% Dip Amid Margin Pressures and Mixed Market Moves

Why is Amanta Healthcare Ltd falling/rising?

As of 03-Jun, Amanta Healthcare Ltd's stock price is rising, currently at 120.75, which reflects an increase of 5.65 or 4.91%. This upward movement follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. The stock has outperformed its sector by 7.49% today, suggesting strong relative performance compared to its peers.Additionally, the stock reached an intraday high of Rs 124.05, marking a 7.78% increase at its peak during the trading day. The rise in investor participation is also notable, with delivery volume on June 2 increasing by 233.48% compared to the five-day average, indicating heightened interest from investors. Despite a negative performance over the past week and month, where the stock fell by 8.28% and 8.14% respectively, the year-to-date performance shows a positive return of 11.09%, contrasting with the Sensex's decline of 12.76% in the same period. This suggests that while there have been recent challenges, the stock's overall performance this year has been robust, contributing to its current rise.

AMANTA Share Price | Amanta Healthcare Ltd Stock Analysis & Recommendation

Q: Are Amanta Healthcare Ltd latest results good or bad?

Amanta Healthcare Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹5.53 crores for Q4 FY26, which is a significant increase of 19.44% compared to the previous quarter. Additionally, revenue grew by 6.84% year-on-year, reaching ₹76.99 crores, marking the highest quarterly revenue in recent times.However, there are notable concerns as well. The operating margin has declined to 19.42%, down from 20.62% in the previous quarter and significantly lower than 26.31% in the same quarter last year. This decline indicates potential challenges in pricing power or increased costs, which could affect profitability moving forward.Moreover, while the company has shown some improvement in net profit, it remains below the previous year's figures, reflecting ongoing operational challenges. The average return on equity (ROE) of 8.18% and return on capital employed (ROCE) of 13.97% over the past five years suggest that the company is facing issues with capital efficiency and profitability.In summary, while there are positive aspects such as revenue growth and improved net profit, the decline in margins and underlying operational challenges indicate that the results are not entirely favorable. The company is at a critical juncture, needing to address these issues to ensure sustainable growth and profitability.

Key Events This Week

18 May: Stock opens at Rs.124.40, declines 4.16%

19 May: Sharp rebound of 7.15% post Q4 FY26 results announcement

20 May: Stock retreats 5.25% amid margin pressure concerns

22 May: Week closes at Rs.129.05, down 0.58% for the week

Week Open

Rs.124.40

Week Close

Rs.129.05Read full news article

Are Amanta Healthcare Ltd latest results good or bad?

Amanta Healthcare Ltd's latest financial results for Q4 FY26 reflect a complex operational landscape. The company reported net sales of ₹76.99 crores, marking a sequential increase of 3.36% from the previous quarter and a year-on-year growth of 6.84%. This indicates some positive momentum in revenue generation, potentially suggesting improved market penetration or product portfolio expansion. However, the operational efficiency metrics reveal challenges. The net profit for the quarter rose to ₹5.53 crores, a 19.44% increase from Q3 FY26, driven by lower interest costs and a slight uptick in other income. Despite this, the net profit remains below the previous year's figure, highlighting ongoing profitability concerns. The operating margin contracted to 19.42%, down from 20.62% in the prior quarter, indicating significant cost pressures or pricing challenges that may affect the company's ability to maintain...

Read full news article

[ { "link": "quarterly", "btn_text": "All Quarterly Results", "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ", "rhs": [ { "prefix": "Net Sales ", "suffix": "QoQ Growth in quarter ended Mar 2026 is 3.36% vs 5.08% in Dec 2025", "dir": -1 }, { "prefix": "Standalone Net Profit ", "suffix": "QoQ Growth in quarter ended Mar 2026 is 19.44% vs 282.64% in Dec 2025", "dir": -1 } ], "table": { "header": [ "Mar'26", "Dec'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "76.99", "val2": "74.49", "chgp": "3.36%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "14.95", "val2": "15.36", "chgp": "-2.67%", "chgp_class": "negative" }, { "field": "Interest", "val1": "4.25", "val2": "5.06", "chgp": "-16.01%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "5.53", "val2": "4.63", "chgp": "19.44%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "19.42%", "val2": "20.62%", "chgp": "-1.20%", "chgp_class": "negative" } ] } }, { "link": "half-yearly", "btn_text": "All Half Yearly Results", "header": "Half Yearly Results Snapshot (Standalone) - Sep'25", "rhs": [ { "prefix": "Net Sales ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 }, { "prefix": "Standalone Net Profit ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 } ], "table": { "header": [ "Sep'25", "Sep'24", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "136.19", "val2": "134.83", "chgp": "1.01%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "29.54", "val2": "27.28", "chgp": "8.28%", "chgp_class": "positive" }, { "field": "Interest", "val1": "11.44", "val2": "15.77", "chgp": "-27.46%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "-2.63", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "4.71", "val2": "1.90", "chgp": "147.89%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "21.69%", "val2": "20.23%", "chgp": "1.46%", "chgp_class": "positive" } ] } }, { "link": "nine-monthly", "btn_text": "All Nine Monthly Results", "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25", "rhs": [ { "prefix": "Net Sales ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 }, { "prefix": "Standalone Net Profit ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 } ], "table": { "header": [ "Dec'25", "Dec'24", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "210.68", "val2": "202.64", "chgp": "3.97%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "44.90", "val2": "42.34", "chgp": "6.05%", "chgp_class": "positive" }, { "field": "Interest", "val1": "16.50", "val2": "21.67", "chgp": "-23.86%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "-2.63", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "9.34", "val2": "6.18", "chgp": "51.13%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "21.31%", "val2": "20.89%", "chgp": "0.42%", "chgp_class": "positive" } ] } }, { "link": "annual", "btn_text": "All Annual Results", "header": "Annual Results Snapshot (Standalone) - Mar'26", "rhs": [ { "prefix": "Net Sales ", "suffix": "YoY Growth in year ended Mar 2026 is 4.72% vs -2.01% in Mar 2025", "dir": 1 }, { "prefix": "Standalone Net Profit ", "suffix": "YoY Growth in year ended Mar 2026 is 41.71% vs 189.26% in Mar 2025", "dir": -1 } ], "table": { "header": [ "Mar'26", "Mar'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "287.68", "val2": "274.71", "chgp": "4.72%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "59.86", "val2": "59.67", "chgp": "0.32%", "chgp_class": "positive" }, { "field": "Interest", "val1": "20.75", "val2": "27.95", "chgp": "-25.76%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "-2.63", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "14.88", "val2": "10.50", "chgp": "41.71%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "20.81%", "val2": "21.72%", "chgp": "-0.91%", "chgp_class": "negative" } ] } } ]